BioCentury
ARTICLE | Distillery Therapeutics

Cancer

May 16, 2017 2:06 PM UTC

Cell culture studies suggest that artificial vesicles loaded with Zybrestat fosbretabulin and doxorubicin could help treat doxorubicin-resistant breast cancer. The artificial vesicles consisted of amphiphilic block co-polymers loaded with Zybrestat fosbretabulin and doxorubicin. In a doxorubicin-resistant human breast cancer cell line, the vesicles decreased growth, spheroid growth, and activity of the drug resistance markers PRKCA and ABCB1, and increased apoptosis compared with free doxorubicin, free Zybrestat or artificial vesicles loaded with Zybrestat or doxorubicin alone. Next steps could include testing the drug-loaded artificial vesicles in animal models of doxorubicin-resistant breast cancer...